Skip to main content

Table 4 Relationships between clinicopathological characteristics and pathological response evaluated by CAP-TRG system

From: Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China

Characteristics

Total cases (n = 192), no. (%)

CAP-TRG

P value

0 (n = 11), no. (%)

1 (n = 23), no. (%)

2 (n = 40), no. (%)

3 (n = 118), no. (%)

Gender

     

0.134

 Male

139 (72.4)

10 (7.2)

20 (14.4)

29 (20.9)

80 (57.6)

 

 Female

53 (27.6)

1 (1.9)

3 (5.7)

11 (20.8)

38 (71.7)

 

Age

     

0.880

 < 55y

89 (46.4)

6 (6.7)

10 (11.2)

17 (19.1)

56 (62.9)

 

 ≥ 55y

103 (53.6)

5 (4.9)

13 (12.6)

23 (22.3)

62 (60.2)

 

Location

     

0.525

 Esophagogastric junction

44 (22.9)

1 (2.3)

4 (9.1)

8 (18.2)

31 (70.5)

 

 Proximal gastric

71 (37)

7 (9.9)

8 (11.3)

15 (21.1)

41 (57.7)

 

 Distal gastric

77 (40.1)

3 (3.9)

11 (14.3)

17 (22.1)

46 (59.7)

 

Maximal diameter of tumor bed

     

0.013

 < 4.5 cm

108 (56.2)

9 (8.3)

20 (18.5)

20 (18.5)

59 (54.6)

 

 4.5–8 cm

64 (33.3)

1 (1.6)

3 (4.7)

17 (26.6)

43 (67.2)

 

 > 8 cm

20 (10.4)

1 (5)

0 (0)

3 (15)

16 (80)

 

Histological differentiation

     

0.002

 Well-moderate

45 (23.4)

4 (8.9)

12 (26.7)

9 (20)

20 (44.4)

 

 Poor

147 (76.6)

7 (4.8)

11 (7.5)

31 (21.1)

98 (66.7)

 

Laurén classification

     

0.143

 Intestinal

77 (40.1)

4 (5.2)

14 (18.2)

14 (19.2)

47 (64.4)

 

 Diffuse

73 (38)

7 (9.6)

5 (6.8)

10 (23.8)

28 (66.7)

 

 Mixed

42 (21.9)

0 (0)

4 (9.5)

15 (35.7)

23 (54.8)

 

LVI

     

<0.001

 Negative

94 (49)

11 (11.7)

19 (20.2)

28 (29.8)

36 (38.3)

 

 Positive

98 (51)

0 (0)

4 (4.1)

12 (12.2)

82 (83.7)

 

PNI

     

<0.001

 Negative

76 (39.6)

11 (14.5)

22 (28.9)

13 (17.1)

30 (39.5)

 

 Positive

116 (60.4)

0 (0)

1 (0.9)

27 (23.3)

88 (75.9)

 

AJCC ypT category

     

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

0 (0)

 

 1

20 (10.4)

0 (0)

12 (60)

5 (25)

3 (15)

 

 2

23 (12)

0 (0)

5 (21.7)

6 (26.1)

12 (52.2)

 

 3

57 (29.7)

0 (0)

5 (8.8)

18 (31.6)

34 (59.6)

 

 4

81 (42.2)

0 (0)

1 (1.2)

11 (13.6)

69 (85.2)

 

AJCC ypN category

     

<0.001

 0

55 (28.6)

9 (16.4)

13 (23.6)

17 (30.9)

16 (29.1)

 

 1

36 (18.8)

0 (0)

6 (16.7)

7 (19.4)

23 (63.9)

 

 2

50 (26)

0 (0)

3 (6)

10 (20)

37 (74)

 

 3

51 (26.6)

2 (3.9)

1 (2)

6 (11.8)

42 (82.4)

 

AJCC stage

     

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

0 (0)

 

 1

24 (12.5)

0 (0)

14 (58.3)

7 (29.2)

3 (12.5)

 

 2

53 (27.6)

2 (3.8)

6 (11.3)

14 (26.4)

31 (58.5)

 

 3

106 (55.2)

0 (0)

3 (2.8)

19 (17.9)

84 (79.2)

 

R0 resection

     

0.212

 Yes

159 (82.8)

11 (6.9)

20 (12.6)

35 (22)

93 (58.5)

 

 No

33 (17.2)

0 (0)

3 (9.1)

5 (15.2)

25 (75.8)

 

Adjuvant chemotherapy

     

0.69

 Not received

59 (30.7)

3 (5.1)

6 (10.2)

10 (16.9)

40 (67.8)

 

 Received

133 (69.3)

8 (6)

17 (35.3)

30 (22.6)

78 (58.6)

 
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us